ArticleBMC psychiatry2025
Financial incentives and long-acting injectable antipsychotics engagement: community mental health professionals' perspectives.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLong-Acting injectable (LAI) antipsychotics prevent relapse in patients with unreliable adherence to oral antipsychotics. Non-engagement with treatment is associated with relapse and involuntary admission. Financial incentives have been shown to increase engagement with LAI antipsychotics among those at highest risk of relapse. This study aimed to explore whether community mental health professionals who deliver LAI antipsychotics find financial incentives acceptable and whether empirical research has addressed their concerns.
methodsFourteen mental health professionals who deliver LAI antipsychotics were interviewed after snowball recruitment. Each then saw a presentation outlining recent research findings into financial incentives for LAI antipsychotic engagement before interviews resumed. Interviews explored the advantages and challenges professionals anticipated with respect to financial incentives for LAIs. Thematic analysis was conducted and themes were compared with findings from the literature.
resultsMedian self-reported support increased from “5/10” to “6.75/10” after the information presentation. Participants responded positively to the idea that incentives could be seen as ‘rewards’. They readily drew connections between improvements in engagement, increased insight, and stronger therapeutic relationships. Practical implementation challenges were envisioned along with proposed solutions. Several participants remained concerned that financial incentives would lead to increased drug use.
conclusionsMental health professionals who deliver LAI antipsychotics hold a range of views about the potential role of financial incentives to increase engagement. When professionals are aware of research findings they are more positive about incentives. Further research should consider patients’ and professionals’ preferences for the design of incentive regimes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.